Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANVS Annovis Bio, Inc.

Closed 08-17 16:00:00 EDT

1.74

-0.11

-5.95%

盘后1.79

+0.05+2.87%

19:49 EDT

High1.85	Low1.74	Vol661.97K
Open1.82	D1 Closing1.85	Amplitude5.95%
Mkt Cap74.02M	Tradable Cap61.46M	Total Shares42.54M
T/O1.19M	T/O Rate1.87%	Tradable Shares35.32M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ANVS","market":"US","secType":"STK","nameCN":"Annovis Bio, Inc.","latestPrice":1.74,"timestamp":1786996800000,"preClose":1.85,"halted":0,"volume":661966,"hourTrading":{"tag":"盘后","latestPrice":1.79,"preClose":1.74,"latestTime":"19:49 EDT","volume":2337,"amount":4130.2502,"timestamp":1787010597831,"change":0.05,"changeRate":0.028736,"amplitude":0.028736},"delay":0,"changeRate":-0.05945945945945951,"floatShares":35319700,"shares":42541900,"eps":-1.767283,"marketStatus":"Closed","change":-0.11,"latestTime":"08-17 16:00:00 EDT","open":1.82,"high":1.85,"low":1.74,"amount":1192243.8599866,"amplitude":0.059459,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.767283,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787040000000},"marketStatusCode":5,"adr":0,"listingDate":1580274000000,"exchange":"NYSE","adjPreClose":1.85,"preHourTrading":{"tag":"盘前","latestPrice":1.86,"preClose":1.85,"latestTime":"04:00 EDT","volume":43,"amount":79.98,"timestamp":1786953615842,"change":0.01,"changeRate":0.005405,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.79,"preClose":1.74,"latestTime":"19:49 EDT","volume":2337,"amount":4130.2502,"timestamp":1787010597831,"change":0.05,"changeRate":0.028736,"amplitude":0.028736},"volumeRatio":1.166562,"impliedVol":0.2033,"impliedVolPercentile":0.1036},"requestUrl":"/m/hq/s/ANVS/","defaultTab":"news","newsList":[{"id":"2660891784","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2660891784","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660891784?lang=en_us&edition=fundamental","pubTime":"2026-08-17 18:00","pubTimestamp":1786960800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Company                                   Symbol     Quarter  Mean  Report Time. ·Amer Sports Inc.                                  2Q       .11    6:00 AM. ·Home Depot Inc.                                   2Q      4.73    6:00 AM. ·Pony AI ADR                                     2Q      (.15)   5:00 AM. ·BILL Hldgs Inc                                  4Q       .71    4:01 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLO","CNSY","FBRX","LOW","ADI","AS","KEYS","KC","MRKR","LZB","BEKE","JKHY","HD","KLAR","ATHM","ADIL","ZTO","CAAP","LYTS","ANF","DCGO","ANVS","HSAI","BEEM","LONA","FUTU","DE","HTHT","DOMO","HAIN","IQ","FN","AAP","COTY","GGAL","BABA","FLNG","ALVO","FLUX","BILL","IMTX","NDSN","ATAT","BIDU","MBRX","XP","BJ","EL","MRCY","BMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659154142","title":"Annovis Bio Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659154142","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659154142?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:53","pubTimestamp":1786715587,"startTime":"0","endTime":"0","summary":"Annovis Bio Inc reports results for the quarter ended June 30 - Earnings SummaryAnnovis Bio IncANVS.Nreported a quarterly adjusted loss of 40 cents per share for the quarter ended June 30, lower than ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B0Y8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659966149","title":"Annovis Bio Q2 Loss Widens as R&D Costs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2659966149","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659966149?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:15","pubTimestamp":1786709731,"startTime":"0","endTime":"0","summary":"Annovis Bio Q2 loss widens as R&D costs riseOverviewUS biotech firm's Q2 net loss per share widened yr/yrCompany fully enrolled pivotal Phase 3 Alzheimer's trial, exceeding original targetQ2 research ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0EG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS","CRMD","PMN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659638149","title":"Annovis Bio Q2 EPS $(0.40) Beats $(0.45) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659638149","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659638149?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:10","pubTimestamp":1786709418,"startTime":"0","endTime":"0","summary":"Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.45) by 11.11 percent. This is a 25 percent decrease over losses of $(0.32) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61205612/annovis-bio-q2-eps-0-40-beats-0-45-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659514935","title":"Annovis Bio Q2 EPS USD -0.4","url":"https://stock-news.laohu8.com/highlight/detail?id=2659514935","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659514935?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:05","pubTimestamp":1786709135,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nPLXR3MNB5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659099146","title":"Press Release: Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659099146","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659099146?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:01","pubTimestamp":1786708860,"startTime":"0","endTime":"0","summary":"-- Pivotal Phase 3 Alzheimer's disease  trial is fully enrolled with a. total number of 850 patients, exceeding original projections.-- Parkinson's disease  open-label extension  study has enrolled. 266 patients with full enrollment projected in Q4 2026.-- Annovis will host a corporate update webinar on Wednesday, September 2,-- Patients: The pivotal Phase 3 AD trial includes patients diagnosed with. early AD  who are also positive for plasma pTau217 biomarker,confirming the presence of amyloid and tau pathology in the brain.-- Study design: The study measures cognition  and function. pTau217, and other biomarkers to evaluate changes in disease pathology.The study is designed to test both symptomatic  and. -- Timeline: The Company plans a database lock for the 6-month analysis in. Q1 2027, with the top-line symptomatic data readout anticipated in the. same quarter. The disease-modifying data readout is expected a year. later.Alzheimer's disease -- OLE study-- Start: The AD OLE study is","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","LU1169589451.USD","AD","DBS","LU1169590202.USD","BK4139","PD","BK4132","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657642687","title":"Annovis Bio Inc Expected to Post a Loss of 45 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657642687","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657642687?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:58","pubTimestamp":1786114699,"startTime":"0","endTime":"0","summary":"Annovis Bio Inc <ANVS.N> expected to post a loss of45cents a share - Earnings PreviewAnnovis Bio IncANVS.N,ANVS.Kis expected to  show no change in quarterly revenue when it reports  results on August ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4441S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650018460","title":"Annovis Bio Completes Enrollment in Pivotal Alzheimer’s Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2650018460","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650018460?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:31","pubTimestamp":1783679463,"startTime":"0","endTime":"0","summary":"Annovis Bio ( ($ANVS) ) has provided an announcement. On July 7, 2026, Annovis Bio announced it had reached full enrollment in its pivotal Phase 3 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-completes-enrollment-in-pivotal-alzheimers-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-completes-enrollment-in-pivotal-alzheimers-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650181831","title":"Annovis Bio Completes Enrollment in Phase 3 Early Alzheimer’s Trial of Buntanetap","url":"https://stock-news.laohu8.com/highlight/detail?id=2650181831","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650181831?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:04","pubTimestamp":1783677887,"startTime":"0","endTime":"0","summary":"Annovis Bio completes enrollment in Phase 3 early Alzheimer’s trial of buntanetapAnnovis Bio reached full enrollment in its pivotal Phase 3 trial of buntanetap for early Alzheimer’s disease.Trial enro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL1Pwg9w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650913794","title":"Analysts’ Top Healthcare Picks: Evolus (EOLS), Annovis Bio (ANVS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650913794","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650913794?lang=en_us&edition=fundamental","pubTime":"2026-07-09 03:20","pubTimestamp":1783538403,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Evolus (EOLS) and Annovis Bio (ANVS) with bullish se...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-evolus-eols-annovis-bio-anvs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-evolus-eols-annovis-bio-anvs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","EOLS","ANVS","LABU","LU0029874061.USD","BK4007","BK4137","XLV","XBI","BK4581","HCSG","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649096494","title":"Annovis Bio Initiated at Buy by Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2649096494","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649096494?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:18","pubTimestamp":1783502280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANVS/analyst-ratings(END) Dow Jones NewswiresJuly 08, 2026 05:18 ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649393039","title":"Annovis Bio initiated with a Buy at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2649393039","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649393039?lang=en_us&edition=fundamental","pubTime":"2026-07-08 04:16","pubTimestamp":1783455373,"startTime":"0","endTime":"0","summary":"Roth Capital initiated coverage of Annovis Bio (ANVS) with a Buy rating and $8 price target The firm is bullish on the company’s Alzheimer’s diseas...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/annovis-bio-initiated-with-a-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/annovis-bio-initiated-with-a-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984461","title":"Annovis Bio announces full enrollment for buntanetap trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649984461?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:20","pubTimestamp":1783423230,"startTime":"0","endTime":"0","summary":"Annovis Bio (ANVS) announced full enrollment of its pivotal Phase 3 trial evaluating buntanetap in patients with early AD. The trial enrolled 850 p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/annovis-bio-announces-full-enrollment-for-buntanetap-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/annovis-bio-announces-full-enrollment-for-buntanetap-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS","BK4139","BBC","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649848839","title":"Annovis Bio Reaches Full Enrollment in Phase 3 Early Alzheimer’s Trial of Buntanetap","url":"https://stock-news.laohu8.com/highlight/detail?id=2649848839","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649848839?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:02","pubTimestamp":1783422173,"startTime":"0","endTime":"0","summary":"Annovis Bio reaches full enrollment in Phase 3 early Alzheimer’s trial of buntanetapAnnovis Bio reached full enrollment of 850 patients in its pivotal Phase 3 trial of buntanetap for early Alzheimer’s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL148HpX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","SG9999014021.USD","SG9999014039.USD","BK4588","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2W23.USD","ANVS","IE00BKPKM429.USD","NDAQ","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4112","BK4139","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649981755","title":"Annovis Bio - Symptomatic Data Readout Expected Q1 2027, Disease-modifying Data Readout Expected Q1 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2649981755","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649981755?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA1XQFTX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649981714","title":"Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2649981714","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649981714?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA1XQFTX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649398175","title":"Annovis Bio - Preparing for Two Nda Submissions Following Data Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2649398175","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649398175?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA1XQFTX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648100205","title":"Press Release: Annovis Appoints Cheng Fang, Ph.d., as Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2648100205","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648100205?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:01","pubTimestamp":1782907260,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (\"Annovis\" or the \"Company\"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4132","ANVS","BK4023","LU1169589451.USD","LU1169590202.USD","PD","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644727510","title":"Annovis Bio Shareholders Approve Governance and Compensation Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2644727510","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644727510?lang=en_us&edition=fundamental","pubTime":"2026-06-18 06:35","pubTimestamp":1781735737,"startTime":"0","endTime":"0","summary":"Annovis Bio ( ($ANVS) ) has issued an announcement. On June 17, 2026, Annovis Bio, Inc. held its 2026 Annual Meeting of Stockholders virtually, wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-shareholders-approve-governance-and-compensation-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-shareholders-approve-governance-and-compensation-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644724896","title":"Annovis Bio shareholders approve 2019 equity plan share increase to 5.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644724896","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644724896?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:51","pubTimestamp":1781729482,"startTime":"0","endTime":"0","summary":"Annovis Bio held its annual shareholder meeting on June 17, 2026.Shareholders backed a slate of director nominees for one-year terms.Ernst & Young was ratified as independent auditor.Investors adopted an amendment to the 2019 Equity Incentive Plan, lifting the share reserve to 5.5 million from 4 million.Shareholders endorsed a two-year cadence for future advisory votes on executive pay; the board expects to follow that schedule.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL8hDHB6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.annovisbio.com","stockEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":0.0278},{"period":"3month","weight":-0.1019},{"period":"6month","weight":-0.2194},{"period":"1year","weight":-0.3199},{"period":"ytd","weight":-0.4653}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.040659},{"month":2,"riseRate":0.285714,"avgChangeRate":0.058949},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.056117},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.132244},{"month":5,"riseRate":0.571429,"avgChangeRate":0.255652},{"month":6,"riseRate":0.428571,"avgChangeRate":0.139284},{"month":7,"riseRate":0.571429,"avgChangeRate":0.075716},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.052143},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.058484},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.073043},{"month":11,"riseRate":0.666667,"avgChangeRate":0.26823},{"month":12,"riseRate":0.333333,"avgChangeRate":0.124011}],"exchange":"NYSE","name":"Annovis Bio, Inc.","nameEN":"Annovis Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Annovis Bio, Inc.,ANVS,Annovis Bio, Inc.股票,Annovis Bio, Inc.股票老虎,Annovis Bio, Inc.股票老虎国际,Annovis Bio, Inc.行情,Annovis Bio, Inc.股票行情,Annovis Bio, Inc.股价,Annovis Bio, Inc.股市,Annovis Bio, Inc.股票价格,Annovis Bio, Inc.股票交易,Annovis Bio, Inc.股票购买,Annovis Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction